Pharmacy Department, Children's Wisconsin, 8915 West Connell Court, Milwaukee, WI, 53226, USA.
Department of Emergency Medicine, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI, 53226, USA.
Cardiovasc Toxicol. 2022 Sep;22(9):866-877. doi: 10.1007/s12012-022-09764-4. Epub 2022 Aug 5.
Many drugs carry some risk of QT interval prolongation, which can lead to life-threatening dysrhythmias including Torsades de Pointes (TdP). CredibleMeds.org identifies medications categorized as "Known Risk of TdP" but does not stratify risk in acute supratherapeutic ingestions. We sought to determine the proportion of cases exhibiting QTc prolongation and life-threatening dysrhythmias including ventricular tachycardia (VT)/ventricular fibrillation (VF), TdP, and asystole in patients exposed to these substances. Retrospective chart review of cases reported to our Regional Poison Center from 2014 to 2019 of exposures to one or more of the "Known Risk" substances was performed. Demographics, therapies, clinical effects, and medical outcome for each case were analyzed. There were 1125 exposures, of which 760 had a documented QTc interval. QTc ≥ 500 ms was reported in 138 (18.2%) of the 760 cases. The most common "Known Risk" substances were citalopram, escitalopram and cocaine. Although not in the "Known Risk" category, mirtazapine, amitriptyline, diphenhydramine, and trazodone had a statistically significant association with QTc > 500 ms. Life-threatening dysrhythmias occurred in 13 cases, with VT/VF in 6 of the 760 (0.8%) cases, and one case of TdP. Flecainide (OR 11.1, 95% CI 2.2-55.8) and methadone (OR 7.1, 95% CI 2.1-23.4) were associated with increased risk of all life-threatening dysrhythmias. Exposures to medications on the Credible Meds list of "Known Risk of TdP" QTc prolongation is common, but life-threatening dysrhythmias are rare. Mirtazapine, amitriptyline, diphenhydramine, and trazodone were associated with prolonged QTc. Flecainide and methadone had the highest associated risk of life-threatening dysrhythmias.
许多药物都有导致 QT 间期延长的风险,从而导致危及生命的心律失常,包括尖端扭转型室性心动过速(TdP)。CredibleMeds.org 确定了被归类为“TdP 已知风险”的药物,但并未对急性超治疗剂量摄入进行风险分层。我们旨在确定在接触这些物质的患者中,表现出 QT 间期延长和危及生命的心律失常(包括室性心动过速/心室颤动(VT/VF)、TdP 和心搏停止)的病例比例。对我们地区毒物中心 2014 年至 2019 年报告的接触一种或多种“已知风险”物质的病例进行了回顾性图表审查。分析了每个病例的人口统计学、治疗、临床效果和医疗结局。共有 1125 例暴露,其中 760 例有记录的 QT 间期。在 760 例中有 138 例(18.2%)报告 QTc≥500ms。最常见的“已知风险”物质是西酞普兰、艾司西酞普兰和可卡因。尽管不在“已知风险”类别中,但米氮平、阿米替林、苯海拉明和曲唑酮与 QTc>500ms 有统计学显著关联。13 例发生危及生命的心律失常,760 例中有 6 例(0.8%)发生 VT/VF,1 例发生 TdP。氟卡尼(OR 11.1,95%CI 2.2-55.8)和美沙酮(OR 7.1,95%CI 2.1-23.4)与所有危及生命的心律失常风险增加相关。接触可信药物列表中的“TdP 已知风险”药物导致 QT 间期延长很常见,但危及生命的心律失常很少见。米氮平、阿米替林、苯海拉明和曲唑酮与 QTc 延长相关。氟卡尼和美沙酮与危及生命的心律失常风险最高相关。